Trial Profile

A pivotal trial of Elsunersen (PRAX-222) for the treatment of Developmental and Epileptic Encephalopathy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 May 2025 According to Praxis Precision Medicines media release, company presented new data from this trial, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025.
08 Apr 2025 According to Praxis Precision Medicines media release, the company to host a virtual investor event on Friday, May 2, 2025 to give update on this trial.
28 Feb 2025 According to a Praxis Precision Medicines, company anticipated to start enrolling patients by mid-year 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com